**Supplemental Digital Content 1: Study profile.** In the initial trial Nepalese infants were randomized to receive PCV10 at 6 and 10 weeks of age followed by a 9-month booster or 6 and 14 weeks of age followed by a 9-month booster. These children were recruited for the current study between 2-3 years of age.

Total participants to follow up in this study

(n=287)

6+10 group

(n=143)

6+14 group

(n= 144)

Followed up and included in the study

(n=108)

Followed up and included in the study

(n=112)

Total participants completed this study

(n=220)

Not included in the study

* Loss to follow up (n=4)
* Moved away(n=4)
* Refused blood draw (n=9)
* Refused for other reason (n=18)

Not included in the study

* Loss to follow up (n=7)
* Moved away (n=8)
* Refused blood draw (n=6)
* Refused for other reason (n=11)